A-M Hvas1, S Juul, E Nexø, J Ellegaard. 1. Department of Haematology, AAS, Aarhus University Hospital, Aarhus Kommunehospital, Nørrebrogade 44, 8000 Aarhus C, Denmark. am.hvas@dadlnet.dk
Abstract
OBJECTIVE: To examine the hypothesis that treatment with vitamin B-12 improves health-related quality of life (HRQOL) in individuals with biochemical signs of vitamin B-12 deficiency. DESIGN: A randomized placebo-controlled study. SETTING: Municipality of Aarhus, Denmark. SUBJECTS:Nonhospitalized individuals (n = 140) with a modest increase in plasma methylmalonic acid (0.40-2.00 micromol L-1) not previously treated with vitamin B-12. INTERVENTION: The participants were randomized to vitamin B-12 injection treatment or placebo weekly for 4 weeks and re-examined 3 months later. The investigator and the participants were blinded to the intervention. MAIN OUTCOME MEASURE: Change in HRQOL assessed by the SF-36 questionnaire from baseline to follow-up examination 3 months later. RESULTS: The participants reported a significantly worser HRQOL than the age- and sex-matched Danish general population (P < 0.001). However, no change was observed after treatment with vitamin B-12 for seven of eight health dimensions. A significant improvement was found only in general health when compared with the placebo group (P = 0.03). CONCLUSIONS:Vitamin B-12 treatment influenced only one of eight dimensions of HRQOL amongst participants with biochemical signs of vitamin B-12 deficiency. We therefore question the benefit of vitamin B-12 treatment amongst elderly with a modestly increased plasma methylmalonic acid as the only sign of vitamin B-12 deficiency.
RCT Entities:
OBJECTIVE: To examine the hypothesis that treatment with vitamin B-12 improves health-related quality of life (HRQOL) in individuals with biochemical signs of vitamin B-12 deficiency. DESIGN: A randomized placebo-controlled study. SETTING: Municipality of Aarhus, Denmark. SUBJECTS: Nonhospitalized individuals (n = 140) with a modest increase in plasma methylmalonic acid (0.40-2.00 micromol L-1) not previously treated with vitamin B-12. INTERVENTION: The participants were randomized to vitamin B-12 injection treatment or placebo weekly for 4 weeks and re-examined 3 months later. The investigator and the participants were blinded to the intervention. MAIN OUTCOME MEASURE: Change in HRQOL assessed by the SF-36 questionnaire from baseline to follow-up examination 3 months later. RESULTS: The participants reported a significantly worser HRQOL than the age- and sex-matched Danish general population (P < 0.001). However, no change was observed after treatment with vitamin B-12 for seven of eight health dimensions. A significant improvement was found only in general health when compared with the placebo group (P = 0.03). CONCLUSIONS:Vitamin B-12 treatment influenced only one of eight dimensions of HRQOL amongst participants with biochemical signs of vitamin B-12 deficiency. We therefore question the benefit of vitamin B-12 treatment amongst elderly with a modestly increased plasma methylmalonic acid as the only sign of vitamin B-12 deficiency.
Authors: J Vidal-Alaball; C C Butler; R Cannings-John; A Goringe; K Hood; A McCaddon; I McDowell; A Papaioannou Journal: Cochrane Database Syst Rev Date: 2005-07-20
Authors: M C Smith Fawzi; S F Kaaya; J Mbwambo; G I Msamanga; G Antelman; R Wei; D J Hunter; W W Fawzi Journal: HIV Med Date: 2007-05 Impact factor: 3.180
Authors: Elisa J de Koning; Nikita L van der Zwaluw; Janneke P van Wijngaarden; Evelien Sohl; Elske M Brouwer-Brolsma; Harm W J van Marwijk; Anke W Enneman; Karin M A Swart; Suzanne C van Dijk; Annelies C Ham; Nathalie van der Velde; André G Uitterlinden; Brenda W J H Penninx; Petra J M Elders; Paul Lips; Rosalie A M Dhonukshe-Rutten; Natasja M van Schoor; Lisette C P G M de Groot Journal: Nutrients Date: 2016-11-23 Impact factor: 5.717
Authors: Jannique G Z van Uffelen; Marijke J M Chin A Paw; Marijke Hopman-Rock; Willem van Mechelen Journal: Qual Life Res Date: 2007-07-07 Impact factor: 4.147